Zealand Pharma Preps Pipeline For Catalyst-Filled 2020
Biotech’s CEO Hopes For Four US approvals In 2020
Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.
You may also be interested in...
Reductions in blood glucose seen in the SUSTAIN FORTE study using a higher dose of Ozempic may help type 2 diabetes patients further improve their diabetes control, with comparable tolerability to currently approved Ozempic 1.0 mg.
Zealand has been hit by an unexpected Phase III failure for its glucagon analog product dasiglucagon in congenital hyperinsulinism, but all may not be lost for the indication.
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.